Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41,067 | $41,400 | $43,952 | $39,005 |
| % Growth | -0.8% | -5.8% | 12.7% | – |
| Cost of Goods Sold | $21,366 | $21,595 | $23,170 | $20,228 |
| Gross Profit | $19,702 | $19,804 | $20,782 | $18,777 |
| % Margin | 48% | 47.8% | 47.3% | 48.1% |
| R&D Expenses | $3,644 | $4,346 | $4,302 | $3,834 |
| G&A Expenses | $1,114 | $1,175 | $988 | $846 |
| SG&A Expenses | $6,473 | $7,373 | $10,159 | $9,945 |
| Sales & Mktg Exp. | $5,359 | $6,198 | $9,171 | $9,099 |
| Other Operating Expenses | $5,339 | $4,778 | $2,684 | $2,276 |
| Operating Expenses | $15,457 | $16,497 | $17,145 | $16,056 |
| Operating Income | $4,245 | $3,308 | $8,297 | $6,314 |
| % Margin | 10.3% | 8% | 18.9% | 16.2% |
| Other Income/Exp. Net | -$76 | -$43 | -$1,917 | -$2,049 |
| Pre-Tax Income | $4,169 | $3,265 | $4,574 | $6,054 |
| Tax Expense | $657 | $370 | $627 | $1,066 |
| Net Income | $2,770 | $2,386 | $3,731 | $4,729 |
| % Margin | 6.7% | 5.8% | 8.5% | 12.1% |
| EPS | 1.04 | 0.89 | 1.43 | 1.85 |
| % Growth | 16.9% | -37.8% | -22.7% | – |
| EPS Diluted | 1.04 | 0.89 | 1.43 | 1.85 |
| Weighted Avg Shares Out | 2,663 | 2,681 | 2,607 | 2,563 |
| Weighted Avg Shares Out Dil | 2,663 | 2,681 | 2,607 | 2,563 |
| Supplemental Information | – | – | – | – |
| Interest Income | $373 | $364 | $283 | $234 |
| Interest Expense | $1,432 | $1,325 | $964 | $823 |
| Depreciation & Amortization | $3,002 | $3,119 | $2,448 | $1,948 |
| EBITDA | $8,603 | $5,559 | $7,874 | $8,814 |
| % Margin | 20.9% | 13.4% | 17.9% | 22.6% |